Kelsey Breslin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelsey Breslin has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Marnie E. Blewitt
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
9 shared publications - Andrew Keniry
The Walter and Eliza Hall Institute of Medical Research
8 shared publications - Quentin Gouil
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
8 shared publications - Matthew E. Ritchie
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
7 shared publications - Andres Tapia del Fierro
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
4 shared publications - James M. Murphy
The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
4 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome
Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by loss of expression from the active paternal allele at an imprinted cluster on chromosome 15. Current treatments address individual symptoms rather than the underlying cause of disease. Because all patients preserve a normal but epigenetically silenced maternal copy of these genes, activation of this copy offers a potential disease-modifying therapy. Here, we investigated the epigenetic regulator SMCHD1. First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target. Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster. Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus and improved phenotypes in a PWS mouse model. Despite broader genome-wide binding, postearly development targeting of SMCHD1 appeared remarkably safe, supporting its potential for gene activation therapy for PWS.
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Open AccessSMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome
Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by loss of expression from the active paternal allele at an imprinted cluster on chromosome 15. Current treatments address individual symptoms rather than the underlying cause of disease. Because all patients preserve a normal but epigenetically silenced maternal copy of these genes, activation of this copy offers a potential disease-modifying therapy. Here, we investigated the epigenetic regulator SMCHD1. First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target. Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster. Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus and improved phenotypes in a PWS mouse model. Despite broader genome-wide binding, postearly development targeting of SMCHD1 appeared remarkably safe, supporting its potential for gene activation therapy for PWS.
- Open Access
SMCHD1 is a novel target for gene-activation therapy to treat Prader-Willi Syndrome
Prader-Willi Syndrome (PWS) is a neurodevelopmental disorder caused by lack of gene expression from the active paternal allele at an imprinted gene cluster on chromosome 15. Current treatments have limited efficacy as they target individual symptoms rather than the underlying cause of disease. All patients preserve a normal, yet epigenetically-silenced, copy of the PWS cluster genes; activation of this imprinted copy to restore necessary gene expression is an appealing option for tackling the root of the disorder. Here we have addressed the potential to activate these silent maternal genes by targeting the epigenetic regulator Structural Maintenance of Chromosomes Hinge domain containing 1 (SMCHD1). First, we expanded the role of SMCHD1 in repressing the PWS cluster from mice to humans, a critical step if SMCHD1 is to be a drug target. Second, we discovered that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role at only half of the PWS genes. We show that deleting Smchd1 after early development in vivo is effective at causing PWS gene-activation in disease-relevant mouse tissues including hypothalamus, and that this has beneficial effects on phenotypes observed in a PWS mouse model. Despite SMCHD1 having a role in gene silencing elsewhere in the genome, our data suggest that targeting SMCHD1 after early development is remarkably safe. Taken together, these data propose SMCHD1 as a novel target for gene-activation therapy for PWS.
Open AccessSMCHD1 is a novel target for gene-activation therapy to treat Prader-Willi Syndrome
Prader-Willi Syndrome (PWS) is a neurodevelopmental disorder caused by lack of gene expression from the active paternal allele at an imprinted gene cluster on chromosome 15. Current treatments have limited efficacy as they target individual symptoms rather than the underlying cause of disease. All patients preserve a normal, yet epigenetically-silenced, copy of the PWS cluster genes; activation of this imprinted copy to restore necessary gene expression is an appealing option for tackling the root of the disorder. Here we have addressed the potential to activate these silent maternal genes by targeting the epigenetic regulator Structural Maintenance of Chromosomes Hinge domain containing 1 (SMCHD1). First, we expanded the role of SMCHD1 in repressing the PWS cluster from mice to humans, a critical step if SMCHD1 is to be a drug target. Second, we discovered that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role at only half of the PWS genes. We show that deleting Smchd1 after early development in vivo is effective at causing PWS gene-activation in disease-relevant mouse tissues including hypothalamus, and that this has beneficial effects on phenotypes observed in a PWS mouse model. Despite SMCHD1 having a role in gene silencing elsewhere in the genome, our data suggest that targeting SMCHD1 after early development is remarkably safe. Taken together, these data propose SMCHD1 as a novel target for gene-activation therapy for PWS.
- Open Access
DNA binding by ATPase-adjacent domains stimulates SMCHD1 ATPase activity
SMCHD1 is an epigenetic regulator in which heterozygous variants are reported in facioscapulohumeral muscular dystrophy (FSHD), as well as Bosma arhinia microphthalmia syndrome (BAMS). While we have previously shown that SMCHD1 is able to interact with nucleic acids via its hinge domain, we have now identified a second DNA-binding site that is located C-terminal to the ATPase domain and formed by two domains: the Bromo-adjacent homology (BAH) and immunoglobulin-like 1 (IGL-1) domains. Here, we report their mode of DNA-interaction and we present the first high-resolution structure of the wild-type human SMCHD1 ATPase using site-directed mutagenesis and structural analysis via cryo-EM. We also reveal that DNA-binding at the BAH-IGL-1 domains stimulates the ATPase activity of full-length SMCHD1 in vitro , and demonstrate in a mouse model that ATP hydrolysis is essential for SMCHD1 function in vivo . Together, these findings establish bidentate DNA binding and DNA-stimulated ATP hydrolysis as central features of SMCHD1 function, providing new mechanistic insight into how SMCHD1 regulates gene silencing. GRAPHICAL
Open AccessDNA binding by ATPase-adjacent domains stimulates SMCHD1 ATPase activity
SMCHD1 is an epigenetic regulator in which heterozygous variants are reported in facioscapulohumeral muscular dystrophy (FSHD), as well as Bosma arhinia microphthalmia syndrome (BAMS). While we have previously shown that SMCHD1 is able to interact with nucleic acids via its hinge domain, we have now identified a second DNA-binding site that is located C-terminal to the ATPase domain and formed by two domains: the Bromo-adjacent homology (BAH) and immunoglobulin-like 1 (IGL-1) domains. Here, we report their mode of DNA-interaction and we present the first high-resolution structure of the wild-type human SMCHD1 ATPase using site-directed mutagenesis and structural analysis via cryo-EM. We also reveal that DNA-binding at the BAH-IGL-1 domains stimulates the ATPase activity of full-length SMCHD1 in vitro , and demonstrate in a mouse model that ATP hydrolysis is essential for SMCHD1 function in vivo . Together, these findings establish bidentate DNA binding and DNA-stimulated ATP hydrolysis as central features of SMCHD1 function, providing new mechanistic insight into how SMCHD1 regulates gene silencing. GRAPHICAL
- Open Access
- 24 February 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1243
A streamlined workflow for long-read DNA methylation analysis with NanoMethViz and Bioconductor
Long-read sequencing technologies have transformed the field of epigenetics by enabling direct, single-base resolution detection of DNA modifications, such as methylation. This produces novel opportunities for studying the role of DNA methylation in gene regulation, imprinting, and disease. However, the unique characteristics of long-read data, including the modBAM format and extended read lengths, necessitate the development of specialised software tools for effective analysis. The NanoMethViz package provides a suite of tools for loading in long-read methylation data, visualising data at various data resolutions. It can convert the data for use with other Bioconductor software such as bsseq, DSS, dmrseq and edgeR to discover differentially methylated regions (DMRs). In this workflow article, we demonstrate the process of converting modBAM files into formats suitable for comprehensive downstream analysis. We leverage NanoMethViz to conduct an exploratory analysis, visually summarizing differences between samples, examining aggregate methylation profiles across gene and CpG islands, and investigating methylation patterns within specific regions at the single-read level. Additionally, we illustrate the use of dmrseq for identifying DMRs and show how to integrate these findings into gene-level visualization plots. Our analysis is applied to a triplicate dataset of haplotyped long-read methylation data from mouse neural stem cells, allowing us to visualize and compare the characteristics of the parental alleles on chromosome 7. By applying DMR analysis, we recover DMRs associated with known imprinted genes and visualise the methylation patterns of these genes summarised at single-read resolution. Through DMR analysis, we identify DMRs associated with known imprinted genes and visualize their methylation patterns at single-read resolution. This streamlined workflow is adaptable to common experimental designs and offers flexibility in the choice of upstream data sources and downstream statistical analysis tools.
- 24 February 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1243
Open AccessA streamlined workflow for long-read DNA methylation analysis with NanoMethViz and Bioconductor
Long-read sequencing technologies have transformed the field of epigenetics by enabling direct, single-base resolution detection of DNA modifications, such as methylation. This produces novel opportunities for studying the role of DNA methylation in gene regulation, imprinting, and disease. However, the unique characteristics of long-read data, including the modBAM format and extended read lengths, necessitate the development of specialised software tools for effective analysis. The NanoMethViz package provides a suite of tools for loading in long-read methylation data, visualising data at various data resolutions. It can convert the data for use with other Bioconductor software such as bsseq, DSS, dmrseq and edgeR to discover differentially methylated regions (DMRs). In this workflow article, we demonstrate the process of converting modBAM files into formats suitable for comprehensive downstream analysis. We leverage NanoMethViz to conduct an exploratory analysis, visually summarizing differences between samples, examining aggregate methylation profiles across gene and CpG islands, and investigating methylation patterns within specific regions at the single-read level. Additionally, we illustrate the use of dmrseq for identifying DMRs and show how to integrate these findings into gene-level visualization plots. Our analysis is applied to a triplicate dataset of haplotyped long-read methylation data from mouse neural stem cells, allowing us to visualize and compare the characteristics of the parental alleles on chromosome 7. By applying DMR analysis, we recover DMRs associated with known imprinted genes and visualise the methylation patterns of these genes summarised at single-read resolution. Through DMR analysis, we identify DMRs associated with known imprinted genes and visualize their methylation patterns at single-read resolution. This streamlined workflow is adaptable to common experimental designs and offers flexibility in the choice of upstream data sources and downstream statistical analysis tools.
- Open Access
- 17 October 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1243
A streamlined workflow for long-read DNA methylation analysis with NanoMethViz and Bioconductor
Long-read sequencing technologies have transformed the field of epigenetics by enabling direct, single-base resolution detection of DNA modifications, such as methylation. This produces novel opportunities for studying the role of DNA methylation in gene regulation, imprinting, and disease. However, the unique characteristics of long-read data, including the modBAM format and extended read lengths, necessitate the development of specialised software tools for effective analysis. The NanoMethViz package provides a suite of tools for loading in long-read methylation data, visualising data at various data resolutions. It can convert the data for use with other Bioconductor software such as bsseq, DSS, dmrseq and edgeR to discover differentially methylated regions (DMRs). In this workflow article, we demonstrate the process of converting modBAM files into formats suitable for comprehensive downstream analysis. We leverage NanoMethViz to conduct an exploratory analysis, visually summarizing differences between samples, examining aggregate methylation profiles across gene and CpG islands, and investigating methylation patterns within specific regions at the single-read level. Additionally, we illustrate the use of dmrseq for identifying DMRs and show how to integrate these findings into gene-level visualization plots. Our analysis is applied to a triplicate dataset of haplotyped long-read methylation data from mouse neural stem cells, allowing us to visualize and compare the characteristics of the parental alleles on chromosome 7. By applying DMR analysis, we recover DMRs associated with known imprinted genes and visualise the methylation patterns of these genes summarised at single-read resolution. Through DMR analysis, we identify DMRs associated with known imprinted genes and visualize their methylation patterns at single-read resolution. This streamlined workflow is adaptable to common experimental designs and offers flexibility in the choice of upstream data sources and downstream statistical analysis tools.
- 17 October 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1243
Open AccessA streamlined workflow for long-read DNA methylation analysis with NanoMethViz and Bioconductor
Long-read sequencing technologies have transformed the field of epigenetics by enabling direct, single-base resolution detection of DNA modifications, such as methylation. This produces novel opportunities for studying the role of DNA methylation in gene regulation, imprinting, and disease. However, the unique characteristics of long-read data, including the modBAM format and extended read lengths, necessitate the development of specialised software tools for effective analysis. The NanoMethViz package provides a suite of tools for loading in long-read methylation data, visualising data at various data resolutions. It can convert the data for use with other Bioconductor software such as bsseq, DSS, dmrseq and edgeR to discover differentially methylated regions (DMRs). In this workflow article, we demonstrate the process of converting modBAM files into formats suitable for comprehensive downstream analysis. We leverage NanoMethViz to conduct an exploratory analysis, visually summarizing differences between samples, examining aggregate methylation profiles across gene and CpG islands, and investigating methylation patterns within specific regions at the single-read level. Additionally, we illustrate the use of dmrseq for identifying DMRs and show how to integrate these findings into gene-level visualization plots. Our analysis is applied to a triplicate dataset of haplotyped long-read methylation data from mouse neural stem cells, allowing us to visualize and compare the characteristics of the parental alleles on chromosome 7. By applying DMR analysis, we recover DMRs associated with known imprinted genes and visualise the methylation patterns of these genes summarised at single-read resolution. Through DMR analysis, we identify DMRs associated with known imprinted genes and visualize their methylation patterns at single-read resolution. This streamlined workflow is adaptable to common experimental designs and offers flexibility in the choice of upstream data sources and downstream statistical analysis tools.
- Open Access
- 25 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-22
SMCHD1 has separable roles in chromatin architecture and gene silencing that could be targeted in disease
The interplay between 3D chromatin architecture and gene silencing is incompletely understood. Here, we report a novel point mutation in the non-canonical SMC protein SMCHD1 that enhances its silencing capacity at endogenous developmental targets. Moreover, it also results in enhanced silencing at the facioscapulohumeral muscular dystrophy associated macrosatellite-array, D4Z4, resulting in enhanced repression of DUX4 encoded by this repeat. Heightened SMCHD1 silencing perturbs developmental Hox gene activation, causing a homeotic transformation in mice. Paradoxically, the mutant SMCHD1 appears to enhance insulation against other epigenetic regulators, including PRC2 and CTCF, while depleting long range chromatin interactions akin to what is observed in the absence of SMCHD1. These data suggest that SMCHD1’s role in long range chromatin interactions is not directly linked to gene silencing or insulating the chromatin, refining the model for how the different levels of SMCHD1-mediated chromatin regulation interact to bring about gene silencing in normal development and disease.
- 25 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-22
Open AccessSMCHD1 has separable roles in chromatin architecture and gene silencing that could be targeted in disease
The interplay between 3D chromatin architecture and gene silencing is incompletely understood. Here, we report a novel point mutation in the non-canonical SMC protein SMCHD1 that enhances its silencing capacity at endogenous developmental targets. Moreover, it also results in enhanced silencing at the facioscapulohumeral muscular dystrophy associated macrosatellite-array, D4Z4, resulting in enhanced repression of DUX4 encoded by this repeat. Heightened SMCHD1 silencing perturbs developmental Hox gene activation, causing a homeotic transformation in mice. Paradoxically, the mutant SMCHD1 appears to enhance insulation against other epigenetic regulators, including PRC2 and CTCF, while depleting long range chromatin interactions akin to what is observed in the absence of SMCHD1. These data suggest that SMCHD1’s role in long range chromatin interactions is not directly linked to gene silencing or insulating the chromatin, refining the model for how the different levels of SMCHD1-mediated chromatin regulation interact to bring about gene silencing in normal development and disease.
- Open Access
- 25 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Maternal SMCHD1 regulates Hox gene expression and patterning in the mouse embryo
Parents transmit genetic and epigenetic information to their offspring. Maternal effect genes regulate the offspring epigenome to ensure normal development. Here we report that the epigenetic regulator SMCHD1 has a maternal effect onHoxgene expression and skeletal patterning. Maternal SMCHD1, present in the oocyte and preimplantation embryo, prevents precocious activation ofHoxgenes post-implantation. Without maternal SMCHD1, highly penetrant posterior homeotic transformations occur in the embryo.Hoxgenes are decorated with Polycomb marks H2AK119ub and H3K27me3 from the oocyte throughout early embryonic development; however, loss of maternal SMCHD1 does not deplete these marks. Therefore, we propose maternal SMCHD1 acts downstream of Polycomb marks to establish a chromatin state necessary for persistent epigenetic silencing and appropriateHoxgene expression later in the developing embryo. This is a striking role for maternal SMCHD1 in long-lived epigenetic effects impacting offspring phenotype.
- 25 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessMaternal SMCHD1 regulates Hox gene expression and patterning in the mouse embryo
Parents transmit genetic and epigenetic information to their offspring. Maternal effect genes regulate the offspring epigenome to ensure normal development. Here we report that the epigenetic regulator SMCHD1 has a maternal effect onHoxgene expression and skeletal patterning. Maternal SMCHD1, present in the oocyte and preimplantation embryo, prevents precocious activation ofHoxgenes post-implantation. Without maternal SMCHD1, highly penetrant posterior homeotic transformations occur in the embryo.Hoxgenes are decorated with Polycomb marks H2AK119ub and H3K27me3 from the oocyte throughout early embryonic development; however, loss of maternal SMCHD1 does not deplete these marks. Therefore, we propose maternal SMCHD1 acts downstream of Polycomb marks to establish a chromatin state necessary for persistent epigenetic silencing and appropriateHoxgene expression later in the developing embryo. This is a striking role for maternal SMCHD1 in long-lived epigenetic effects impacting offspring phenotype.
- Open Access
- 18 July 2022
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 15 (1) , 1-11
Maternal SMCHD1 controls both imprinted Xist expression and imprinted X chromosome inactivation
Embryonic development is dependent on the maternal supply of proteins through the oocyte, including factors setting up the adequate epigenetic patterning of the zygotic genome. We previously reported that one such factor is the epigenetic repressor SMCHD1, whose maternal supply controls autosomal imprinted expression in mouse preimplantation embryos and mid-gestation placenta. In mouse preimplantation embryos, X chromosome inactivation is also an imprinted process. Combining genomics and imaging, we show that maternal SMCHD1 is required not only for the imprinted expression ofXistin preimplantation embryos, but also for the efficient silencing of the inactive X in both the preimplantation embryo and mid-gestation placenta. These results expand the role of SMCHD1 in enforcing the silencing of Polycomb targets. The inability of zygotic SMCHD1 to fully restore imprinted X inactivation further points to maternal SMCHD1’s role in setting up the appropriate chromatin environment during preimplantation development, a critical window of epigenetic remodelling.
- 18 July 2022
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 15 (1) , 1-11
Open AccessMaternal SMCHD1 controls both imprinted Xist expression and imprinted X chromosome inactivation
Embryonic development is dependent on the maternal supply of proteins through the oocyte, including factors setting up the adequate epigenetic patterning of the zygotic genome. We previously reported that one such factor is the epigenetic repressor SMCHD1, whose maternal supply controls autosomal imprinted expression in mouse preimplantation embryos and mid-gestation placenta. In mouse preimplantation embryos, X chromosome inactivation is also an imprinted process. Combining genomics and imaging, we show that maternal SMCHD1 is required not only for the imprinted expression ofXistin preimplantation embryos, but also for the efficient silencing of the inactive X in both the preimplantation embryo and mid-gestation placenta. These results expand the role of SMCHD1 in enforcing the silencing of Polycomb targets. The inability of zygotic SMCHD1 to fully restore imprinted X inactivation further points to maternal SMCHD1’s role in setting up the appropriate chromatin environment during preimplantation development, a critical window of epigenetic remodelling.
- Open Access
- 29 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
BAF complex-mediated chromatin relaxation is required for establishment of X chromosome inactivation
The process of epigenetic silencing, while fundamentally important, is not yet completely understood. Here we report a replenishable female mouse embryonic stem cell (mESC) system, Xmas, that allows rapid assessment of X chromosome inactivation (XCI), the epigenetic silencing mechanism of one of the two X chromosomes that enables dosage compensation in female mammals. Through a targeted genetic screen in differentiating Xmas mESCs, we reveal that the BAF complex is required to create nucleosome-depleted regions at promoters on the inactive X chromosome during the earliest stages of establishment of XCI. Without this action gene silencing fails. Xmas mESCs provide a tractable model for screen-based approaches that enable the discovery of unknown facets of the female-specific process of XCI and epigenetic silencing more broadly.
- 29 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessBAF complex-mediated chromatin relaxation is required for establishment of X chromosome inactivation
The process of epigenetic silencing, while fundamentally important, is not yet completely understood. Here we report a replenishable female mouse embryonic stem cell (mESC) system, Xmas, that allows rapid assessment of X chromosome inactivation (XCI), the epigenetic silencing mechanism of one of the two X chromosomes that enables dosage compensation in female mammals. Through a targeted genetic screen in differentiating Xmas mESCs, we reveal that the BAF complex is required to create nucleosome-depleted regions at promoters on the inactive X chromosome during the earliest stages of establishment of XCI. Without this action gene silencing fails. Xmas mESCs provide a tractable model for screen-based approaches that enable the discovery of unknown facets of the female-specific process of XCI and epigenetic silencing more broadly.
- Open Access
Maternal SMCHD1 controls both imprinted Xist expression and imprinted X chromosome inactivation
Embryonic development is dependent on the maternal supply of proteins through the oocyte, including factors setting up the adequate epigenetic patterning of the zygotic genome. We previously reported that one such factor is the epigenetic repressor SMCHD1, whose maternal supply controls autosomal imprinted expression in mouse preimplantation embryos and mid-gestation placenta. In mouse preimplantation embryos, X chromosome inactivation is also an imprinted process. Combining genomics and imaging, we show that maternal SMCHD1 is required not only for the imprinted expression of Xist in preimplantation embryos, but also for the efficient silencing of the inactive X in both the preimplantation embryo and mid-gestation placenta. These results expand the role of SMCHD1 in enforcing the silencing of Polycomb targets. The inability of zygotic SMCHD1 to fully restore imprinted X inactivation further points to maternal SMCHD1’s role in setting up the appropriate chromatin environment during preimplantation development, a critical window of epigenetic remodelling.
Open AccessMaternal SMCHD1 controls both imprinted Xist expression and imprinted X chromosome inactivation
Embryonic development is dependent on the maternal supply of proteins through the oocyte, including factors setting up the adequate epigenetic patterning of the zygotic genome. We previously reported that one such factor is the epigenetic repressor SMCHD1, whose maternal supply controls autosomal imprinted expression in mouse preimplantation embryos and mid-gestation placenta. In mouse preimplantation embryos, X chromosome inactivation is also an imprinted process. Combining genomics and imaging, we show that maternal SMCHD1 is required not only for the imprinted expression of Xist in preimplantation embryos, but also for the efficient silencing of the inactive X in both the preimplantation embryo and mid-gestation placenta. These results expand the role of SMCHD1 in enforcing the silencing of Polycomb targets. The inability of zygotic SMCHD1 to fully restore imprinted X inactivation further points to maternal SMCHD1’s role in setting up the appropriate chromatin environment during preimplantation development, a critical window of epigenetic remodelling.